Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Kiromic BioPharma, Inc.

< Previous 1 2 Next >
Kiromic BioPharma Announces Reverse Stock Split
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Favorable Deltacel™ Preclinical Pharmacology Results
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Two Leading Independent Proxy Advisory Firms Recommend Kiromic BioPharma Stockholders Vote “FOR” All Proxy Proposals
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma CEO Issues Letter to Stockholders
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Arranges Up to $10 Million Financing
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Availability of Company’s Current Corporate Presentation
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Highlights
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Biopharma Announces Filing of Form 12b-25
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Changes in Management, Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Appoints Frank Tirelli and Dr. Karen Reeves to Company’s Board of Directors
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma, Now Clinical Stage, Reports Significant Progression Free Survival Benefit in Metastatic Pancreatic Cancer Patient Treated with KiroVax/BSK01, Company’s Phase 1 Cell Therapy Cancer Vaccine Candidate for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Strategic Collaboration with Gemelli Teaching Hospital to Accelerate the Analysis of Allogeneic CAR-T Clinical Trial Candidate Alexis ISO-1 in Solid Cancers
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Announces Chief Financial Officer Transition
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Announces the Acquisition of InSilico Solutions Leveraging on Bioinformatics and Artificial Intelligence to Advance Clinical Development on Its Outpatient Allogeneic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma Provides Update on IND Filings on its Off-the-Shelf, Allogeneic CAR-T for Solid Tumors
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma, Inc. Announces Closing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic BioPharma, Inc. Announces Pricing of Public Offering
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
KRBP Presenting at 2021 Next-Gen Immuno Oncology Congress Showcasing Its Proprietary AI Targets for Off-the-Shelf Allogenic CAR-T for Solid Tumors
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
KRBP Presenting at July 2021 Gamma Delta T Cell Summit to Showcase Our Off-The-Shelf Allogeneic Gamma Delta T Cell Therapy
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Announces Expansion of In-House Cell therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing Officer
From Kiromic BioPharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Announces Identification of Novel Targets for Allogeneic CAR Gamma Delta T-cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
Kiromic Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy
From Kiromic Biopharma, Inc.
Via Business Wire
Tickers KRBP
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.